<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12011">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00526162</url>
  </required_header>
  <id_info>
    <org_study_id>112</org_study_id>
    <nct_id>NCT00526162</nct_id>
  </id_info>
  <brief_title>ConsultaTM CRT-D Clinical Evaluation Study</brief_title>
  <official_title>Clinical Study to Evaluate System Safety and Clinical Performance of the ConsultaTM CRT-D Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Bakken Research Center</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>Italy: Ministry of Health</authority>
    <authority>Denmark: Danish Medicines Agency</authority>
    <authority>Norway: Directorate of Health</authority>
    <authority>Sweden: Medical Products Agency</authority>
    <authority>Netherlands: Dutch Health Care Inspectorate</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Austria: Federal Ministry for Health and Women</authority>
    <authority>Switzerland: Swissmedic</authority>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the Consulta clinical study is to evaluate the overall system safety and
      clinical performance of the Consulta Implantable Cardioverter Defibrillator with Cardiac
      Resynchronization Therapy (CRT-D).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Consulta CRT-D is an investigational bi-ventricular device that provides atrial and
      ventricular tachyarrhythmia detection and therapy, cardioversion, defibrillation and cardiac
      resynchronization therapy.

      The study will be a prospective, non-randomized, multicenter clinical study, conducted in
      approximately 18 centers.

      To allow for sufficient experience with the device, a maximum of 80 subjects may be
      implanted with the Consulta device. Data will be collected at baseline (enrollment),
      implant, 1-, 3-, and 6- months post implant and every 6 months thereafter or until study
      closure (whichever occurs first), unscheduled follow-up visits, System Modifications,
      Technical Observations, Study Deviations, Study Exit, upon notification of new or updated
      Adverse Events and in case of death.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of Subjects With an Unanticipated Serious Adverse Device Effects at 1-Month Post Implant.</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Describe System Performance</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Tachyarrhythmias</condition>
  <condition>Heart Failure</condition>
  <condition>Ventricular Dysfunction</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bi-ventricular Implantable Cardioverter Defibrillator</intervention_name>
    <description>Implantation of a Bi-ventricular Implantable Cardioverter Defibrillator</description>
    <arm_group_label>1</arm_group_label>
    <other_name>ConsultaTM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have an indication for a defibrillator.

          -  Patients who are optimally treated with medication.

          -  Patients who are NYHA Class III or IV

        Exclusion Criteria:

          -  Patients with a life expectancy less than the duration of the study.

          -  Patients with medical conditions that preclude the testing required for all patients
             by the study protocol or that otherwise limit study participation required for all
             patients.

          -  Patients with mechanical tricuspid heart valves.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Consulta Clinical Study Team</last_name>
    <role>Study Chair</role>
    <affiliation>Medtronic Bakken Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital</name>
      <address>
        <city>City</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <lastchanged_date>April 21, 2009</lastchanged_date>
  <firstreceived_date>September 6, 2007</firstreceived_date>
  <firstreceived_results_date>February 6, 2009</firstreceived_results_date>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ventricular Dysfunction</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Device not implanted</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1</title>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="81"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="34"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="47"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="66.0" spread="10.18"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="62"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Germany</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Israel</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>United Kingdom</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Netherlands</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Norway</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Denmark</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Switzerland</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Austria</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>France</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Sweden</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With an Unanticipated Serious Adverse Device Effects at 1-Month Post Implant.</title>
        <description>Only subjects implanted with a Consulta device that were followed at least 28 days post-implant, or have had a unanticipated device effect within 28 days after implant were included in the analysis.</description>
        <time_frame>1 month</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>1</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="80"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Subjects With an Unanticipated Serious Adverse Device Effects at 1-Month Post Implant.</title>
            <description>Only subjects implanted with a Consulta device that were followed at least 28 days post-implant, or have had a unanticipated device effect within 28 days after implant were included in the analysis.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="80"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <param_type>percentage</param_type>
            <param_value>0</param_value>
            <ci_percent>97</ci_percent>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>9.5</ci_upper_limit>
            <estimate_desc>The confidence interval was calculated based on 35 patients who completed 1-month follow-up at interim analysis.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Describe System Performance</title>
        <description>System performance was assessed by reviewing Holter records, Save to disk files and technical observations. Only descriptive statistics were presented,no comparative measure was analyzed. 20 24-hour Holter records and 94 Save to Disk Files were reviewed. 3 minor anomalies were found, and were deemed acceptable. There was no patient safety risk.</description>
        <time_frame>1 month</time_frame>
        <safety_issue>No</safety_issue>
        <population>The device performed as intended.</population>
        <group_list>
          <group group_id="O1">
            <title>1</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="80"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Describe System Performance</title>
            <description>System performance was assessed by reviewing Holter records, Save to disk files and technical observations. Only descriptive statistics were presented,no comparative measure was analyzed. 20 24-hour Holter records and 94 Save to Disk Files were reviewed. 3 minor anomalies were found, and were deemed acceptable. There was no patient safety risk.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="80"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>A total of 70 Adverse Events were reported in 44 subjects.</description>
        <time_frame>1 month</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>1</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="80"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Adverse Events</title>
            <description>A total of 70 Adverse Events were reported in 44 subjects.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="80"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In most cases, contracts allow investigators to publish study results per the publication plan/protocol following Medtronic's review to determine whether confidential information (&quot;CI&quot;) is disclosed. Any such CI is deleted prior to publication/presentation. Medtronic may not censor/interfere with the publication except as described. Investigators may not publish any single-site publications until the main multi-site study publication has occurred.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>CRDM Core Clinical Organization</name_or_title>
      <organization>Medtronic CRDM</organization>
      <phone>800-328-2518</phone>
      <email>jamie.l.reynolds@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
